In Japan, the anti-programmed cell death ligand 1 (PD-L1) antibody, atezolizumab (ATZ), a representative ICI, was approved in September 2020 for combination therapy with the anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody bevacizumab (BEV) for hepatocellular carcinoma. Here, VEGFA is linked to hepatocellular carcinoma.